Global Pharma Manufacturing Surge: October 2025 Drives Massive Job Creation and Facility Expansions Worldwide

October 2025 witnessed an exceptional surge in pharmaceutical and life sciences investments, underscoring global momentum in innovation, regional job creation, and supply chain localization.

Leading organizations — including AstraZeneca, Eli Lilly, Moderna, Simtra BioPharma Solutions, ACG, Rentschler Biopharma, Ypsomed, Lupin, and Edan Instruments — announced landmark manufacturing projects and facility openings.

Simtra BioPharma Expands Dual-Continent Manufacturing Footprint

Location: Halle/Westfalen, Germany

• Simtra BioPharma Solutions, a leading sterile injectables CDMO, advanced its dual-continent expansion in North America and Europe.
• The company inaugurated a new conjugation and purification suite and added two high-speed isolator lines — one for syringes, one for vials.
• Simtra now manufactures six of the 17 approved antibody-drug conjugates (ADCs) worldwide, producing nearly 200 million sterile units annually.

“Our global network enables customers to build resilient supply chains and bring breakthrough oncology treatments to patients faster,” said a company spokesperson.

ACG’s $200 Million U.S. Expansion to Create 200 Jobs

Location: Atlanta, Georgia, USA

• India-based ACG, the world’s most integrated solid-dosage solutions provider, announced a $200 million phased investment in its first U.S. capsule manufacturing facility.
• The facility will strengthen local R&D collaboration, enhance responsiveness, and create more than 200 new jobs by 2027.

“This facility strengthens our ties with customers across the region and marks a new era of local innovation partnerships,” said Karan Singh, Managing Director, ACG.

AstraZeneca’s $4.5 Billion Virginia Facility to Create 3,600 Jobs

Location: Albemarle County, Virginia, USA

• AstraZeneca will invest $4.5 billion to build an advanced biomanufacturing campus at Rivanna Futures.
• The facility will specialize in cancer and specialty medicines, integrating AI, automation, and data analytics for optimized production.
• The project will generate 600 direct jobs and an additional 3,000 construction and support positions.

“This new site represents the future of sustainable, technology-driven biomanufacturing,” said an AstraZeneca spokesperson.

Moderna Opens mRNA Manufacturing Hub in the UK

Location: Harwell Science & Innovation Campus, Oxfordshire, UK

• Moderna inaugurated the Moderna Innovation and Technology Centre (MITC), the UK’s first domestic mRNA vaccine production site.
• The MITC will produce respiratory vaccines for the NHS and expand research into mRNA applications for cancer, rare diseases, and autoimmune disorders.

“This milestone underscores the UK’s commitment to improving health security and advancing mRNA innovation,” said Stéphane Bancel, CEO of Moderna.

Eli Lilly’s $1 Billion Manufacturing Expansion in India

Location: India

• Eli Lilly and Company announced a $1 billion investment to expand contract manufacturing capabilities in India.
• The initiative will create hundreds of new jobs for highly skilled professionals, enhancing medicine access for global markets.
• The expansion supports Lilly’s portfolio in diabetes, obesity, Alzheimer’s, cancer, and autoimmune diseases.

“India’s deep scientific expertise makes it a vital pillar in our global manufacturing strategy,” the company stated.

Lupin’s $250 Million Florida Plant to Generate 200 Jobs

Location: Coral Springs, Florida, USA

• Lupin Limited will invest $250 million over five years in a state-of-the-art respiratory manufacturing plant.
• The facility will produce 25+ critical respiratory medicines, including lifesaving albuterol inhalers.
• Expected to create over 200 skilled jobs in Broward County by 2030.

Ypsomed Launches First U.S. Manufacturing Facility

Location: Holly Springs, North Carolina, USA

• Swiss medtech company Ypsomed announced plans to establish its first U.S. manufacturing site, investing CHF 200 million.
• The 160,000 sq. ft. facility will supply injection and infusion systems for the North American market starting in 2027.
• 100 jobs will be created initially, expanding to 200 as operations scale.

“We are excited to be closer to our U.S. customers and support growing demand through local production,” said a company statement.

Rentschler Biopharma Strengthens German Biotech Hub

Location: Laupheim, Germany

• Rentschler Biopharma SE marked construction progress on its new buffer media station — the largest single investment in the company’s history.
• The expansion enhances sustainable biomanufacturing and reinforces Germany’s role as a European biotech hub.

“We combine innovation with responsibility to ensure sustainable growth for our clients and patients worldwide,” said Benedikt von Braunmühl, CEO of Rentschler Biopharma.

Edan Instruments Opens U.S. Manufacturing Hub

Location: San Diego, California, USA

• Edan Instruments, Inc. opened its first U.S. manufacturing facility, expanding its footprint in medical device innovation.
• The 20,882 sq. ft. site integrates R&D, manufacturing, logistics, and warehousing, boosting production efficiency and service delivery.
• Certified under MDSAP and California FDB, the facility positions Edan to better support U.S. healthcare providers.

“This facility enhances our ability to deliver reliable, locally manufactured medical technologies,” said an Edan spokesperson.

Elevate Holistics Highlights Booming Cannabis Job Market

Location: United States

• Elevate Holistics, a telehealth leader in medical cannabis access, spotlighted the industry’s growing workforce impact.
• The 2025 Vangst Jobs Report shows the legal cannabis sector supports 425,002 full-time equivalent jobs in the U.S.
• Job growth surged in New York (+209%), Mississippi (+103%), and Ohio (+34%), even as mature markets recalibrated.

“The cannabis industry is no longer niche — it’s a career destination,” said Aspen Noonan, CEO of Elevate Holistics.

Global Impact Summary

• Total Announced Investment (October 2025): Over $10 billion
• Jobs Created: More than 10,000 direct and tens of thousands indirect
• Strategic Outcomes:
  • Reinforced local and regional medicine production
  • Strengthened biomanufacturing infrastructure
  • Expanded R&D collaboration and workforce development
  • Enhanced supply chain resilience post-pandemic